Urolithin A,
does it really help with Improvement of mitochondrial function, muscle endurance, and age-related muscle function?
research showsHuman RCTs found improvements in some muscle-endurance measures and mitochondrial-related biomarkers, but the primary endpoints of 6-minute walk distance and muscle ATP production in the older-adult trial did not differ significantly from placebo. The middle-aged trial also did not improve its primary endpoint of peak power output, and the athlete trial found no significant improvement in 3000 m performance or mitochondrial function. The evidence centers on secondary endpoints and biomarker signals rather than clinical functional benefit, and all major trials are manufacturer-linked, so the grade is C.
ads claimMarket materials use expressions such as 'activate mitophagy,' 'cellular energy,' 'restore strength and endurance,' and 'healthy aging.' Human research mainly consists of small, short studies of the specific standardized ingredient Mitopure at 500 to 1,000 mg/day and is not evidence of clinically established slowing of aging.
Useful facts when choosing a product
- Doses in the major RCTs were 500 mg or 1,000 mg daily, and durations ranged from 4 weeks to 4 months.
- The study product was generally the manufacturer's standardized ingredient Mitopure.
- Respiratory capacity, walking, and performance were measured alongside biomarkers such as acylcarnitines, CRP, CK, and mitochondrial proteins.
- In RCTs lasting up to 4 months, a statistical difference in adverse events versus placebo was not identified.
What the research actually shows
In the Liu 2022 double-blind RCT of 66 adults aged 65 to 90 years, 1,000 mg/day for 4 months improved some hand and leg muscle-endurance measures and plasma biomarkers, but the co-primary endpoints of 6-minute walk distance and maximal ATP production in hand muscle were not significant. In the Singh 2022 RCT of 88 participants over 4 months, hamstring strength and some biomarkers improved, but the primary endpoint of peak power output was negative. In the Whitfield 2025 RCT of 42 athletes, 3000 m performance, the between-group difference in VO2max, and mitochondrial function were not significant, with signals only in perceived exertion and some recovery markers. All three trials had Amazentis funding or employee involvement.
Why this is classified as C (43)
There are several human RCTs and positive signals in some muscle-endurance, strength, and biomarker outcomes, placing the evidence above D. However, core functional primary endpoints were repeatedly negative, only manufacturer-linked studies are available, and there is no clinical evidence for prevention of age-related muscle decline, so the grade is C with 43 points.
Counterpoint. Signals in some secondary muscle-endurance and mitochondrial-related biomarker endpoints remain. This judgment reflects those signals together with negative primary endpoints and concentration of funding.
Rejudgment record. Reassessment (cross-check reflected) — The co-primary 6-minute walk and ATP endpoints in the 66-person trial and the primary peak-power endpoint in the 88-person trial were null; positive findings were limited to secondary muscle endurance and acylcarnitines, and Amazentis employees participated in the major trials, supporting C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Mitochondria and muscle endurance | C | Secondary muscle-endurance and acylcarnitine signals were positive, but the co-primary 6-minute walk and ATP endpoints in the 66-person trial and peak power in the 88-person trial were null |
| Age-related muscle function | D | Major functional primary endpoints were null, with no independent long-term clinical replication |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Liu S et al. 2022 | Double-blind randomized placebo-controlled trial | 66 | Amazentis product and investigator linkage | 6-minute walk distance, maximal ATP production, muscle endurance, and plasma biomarkers | The primary endpoints of 6-minute walk distance and maximal ATP production were negative; some secondary muscle-endurance and biomarker outcomes were positive. | Key |
| Singh A et al. 2022 | Randomized double-blind placebo-controlled trial | 88 | Sponsored by Amazentis; multiple authors were employees | Peak power output, leg strength, VO2, 6-minute walk, and biomarkers | The primary endpoint of peak power output was negative, while hamstring strength and some secondary measures showed positive signals. | Key |
| Whitfield J et al. 2025 | Double-blind randomized placebo-controlled trial | 42 | Amazentis research funding and employee involvement | 3000 m performance, VO2max, recovery biomarkers, and mitochondrial function | The 3000 m performance and mitochondrial function outcomes were not significant; perceived exertion and some recovery biomarkers showed positive signals. | Supportive |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-13).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-13 · Corrections: none
Cite this verdict
[Chamgap] Urolithin A x improvement of mitochondrial function, muscle endurance, and age-related muscle function — Evidence Grade C·43. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/sports/urolithin-a-mitochondria-muscle-endurance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.